MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jpeds.2019.07.064

Медицинская библиотека · The Journal of pediatrics · 2019

Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.

Tremoulet Adriana H, Jain Sonia, Jone Pei-Ni, Best Brookie M, Duxbury Elizabeth H, Franco Alessandra, Printz Beth, Dominguez Samuel R, Heizer Heather, Anderson Marsha S, Glodé Mary P, He Feng, Padilla Robert L, Shimizu Chisato, Bainto Emelia, Pancheri Joan, Cohen Harvey J, Whitin John C, Burns Jane C

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVES

To determine the safety, tolerability, pharmacokinetics, and immunomodulatory effects of a 6-week course of atorvastatin in patients with acute Kawasaki disease with coronary artery (CA) aneurysm (CAA).

STUDY

DESIGN

This was a Phase I/IIa 2-center dose-escalation study of atorvastatin (0.125-0.75 mg/kg/day) in 34 patients with Kawasaki disease (aged 2-17 years) with echocardiographic evidence of CAA. We measured levels of the brain metabolite 24(S)-hydroxycholesterol (24-OHC), serum lipids, acute-phase reactants, liver enzymes, and creatine phosphokinase; peripheral blood mononuclear cell populations; and CA internal diameter normalized for body surface area before atorvastatin treatment and at 2 and 6 weeks after initiation of atorvastatin treatment.

RESULTS

A 6-week course of up to 0.75 mg/kg/day of atorvastatin was well tolerated by the 34 subjects (median age, 5.3 years; IQR, 2.6-6.4 years), with no serious adverse events attributable to the study drug. The areas under the curve for atorvastatin and its metabolite were larger in the study subjects compared with those reported in adults, suggesting a slower rate of metabolism in children. The 24-OHC levels were similar between the atorvastatin-treated subjects and matched controls.

CONCLUSIONS

Atorvastatin was safe and well tolerated in our cohort of children with acute Kawasaki disease and CAA. A Phase III efficacy trial is warranted in this patient population, which may benefit from the known anti-inflammatory and immunomodulatory effects of this drug.

Для цитирования: Tremoulet Adriana H, Jain Sonia, Jone Pei-Ni, Best Brookie M, Duxbury Elizabeth H, Franco Alessandra, Printz Beth, Dominguez Samuel R, Heizer Heather, Anderson Marsha S, Glodé Mary P, He Feng, Padilla Robert L, Shimizu Chisato, Bainto Emelia, Pancheri Joan, Cohen Harvey J, Whitin John C, Burns Jane C. Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.. The Journal of pediatrics. 2019. DOI: 10.1016/j.jpeds.2019.07.064.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.